Tonsil‐derived mesenchymal stem cells (T‐MSCs) prevent Th17‐mediated autoimmune response via regulation of the programmed death‐1/programmed death ligand‐1 (PD‐1/PD‐L1) pathway
- 20 January 2017
- journal article
- research article
- Published by Hindawi Limited in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 12 (2), e1022-e1033
- https://doi.org/10.1002/term.2423
Abstract
Our knowledge of the immunomodulatory role of mesenchymal stem cells (MSCs) in both the innate and adaptive immune systems has dramatically expanded, providing great promise for treating various autoimmune diseases. However, the contribution of MSCs to Th17‐dominant immune disease, such as psoriasis and its underlying mechanism remains elusive. In this study, we demonstrated that human palatine tonsil‐derived MSCs (T‐MSCs) constitutively express both the membrane‐bound and soluble forms of programmed death‐ligand 1 (PD‐L1), which enables T‐MSCs to be distinguished from MSCs originating from other organs (i.e. bone marrow or adipose tissue). We also found that T‐MSC‐derived PD‐L1 effectively represses Th17 differentiation via both cell‐to‐cell contact and a paracrine effect. Further, T‐MSCs increase programmed death‐1 (PD‐1) expression on T‐cells by secreting IFN‐β, which may enhance engagement with PD‐L1. Finally, transplantation of T‐MSCs into imiquimod‐induced psoriatic skin inflammation in mice significantly abrogated disease symptoms, mainly by blunting the Th17 response in a PD‐L1‐dependent manner. This study suggests that T‐MSCs might be a promising cell source to treat autoimmune diseases such as psoriasis, via its unique immunoregulatory features. Copyright © 2017 John Wiley & Sons, Ltd.Keywords
This publication has 33 references indexed in Scilit:
- The IL23R A/Gln381 Allele Promotes IL-23 Unresponsiveness in Human Memory T-Helper 17 Cells and Impairs Th17 Responses in Psoriasis PatientsJournal of Investigative Dermatology, 2013
- Mesenchymal stem cell effects on T-cell effector pathwaysStem Cell Research & Therapy, 2011
- Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseasesAutoimmunity Reviews, 2011
- IL-23–Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17AThe Journal of Immunology, 2011
- IL-23 and IL-17A, but Not IL-12 and IL-22, Are Required for Optimal Skin Host Defense against Candida albicansThe Journal of Immunology, 2010
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1International Immunology, 2010
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Mesenchymal stem cells: a new strategy for immunosuppression and tissue repairCell Research, 2010
- Requirement of IFN-γ–Mediated Indoleamine 2,3-Dioxygenase Expression in the Modulation of Lymphocyte Proliferation by Human Adipose–Derived Stem CellsTissue Engineering, Part A, 2009
- PsoriasisThe New England Journal of Medicine, 2009